|
|
Article: BioVex signs exclusive licence to use key antigens in vaccine.(Brief Article)
- Article from:
- BIOTECH Patent News
- Article date:
- September 1, 2002
CopyrightCOPYRIGHT 2002 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioVex Limited (Oxford, England) announced that it has signed a worldwide patent licence agreement with the United States Public Health Service. The agreement allows exclusive use of the key human melanoma antigens, MART-1 and gp100, in therapeutic cancer vaccines based on herpes virus vectors. The melanoma antigens were characterised in the laboratory of Dr. Steven A Rosenberg at the National Cancer Institute, Bethesda and BioVex will utilise them in its novel therapeutic vaccine, ImmunoVEX tri-melan.
Melanoma has the fastest growing incidence of any human cancer in the Western world, growing at 6% per annum. There are around 42,000 new cases diagnosed ...